R J Biotech Current Assets
The Current Assets of R J Biotech (536456.BO) as of Oct 21, 2026 is 2.90 M INR. In the previous year, Current Assets was 36.31 M INR — a change of -92.01% (lower).
Get this data via API
Financial Data API
Current Assets
2.90 MINR
YoY
-92.01%
Last updated:
The R J Biotech Current Assets history
3 Years
10 Years
25 Years
Max
| YEAR | Current Assets | YoY |
|---|---|---|
| 2.90 MINR | -92.01% | |
| 36.31 MINR | -83.57% | |
| 220.99 MINR | -9.20% | |
| 243.38 MINR | -22.74% | |
| 315.03 MINR | -27.59% | |
| 435.05 MINR | -21.29% | |
| 552.71 MINR | -1.38% | |
| 560.45 MINR | +7.18% | |
| 522.90 MINR | +51.08% | |
| 346.10 MINR | +7.72% | |
| 321.30 MINR | +44.47% | |
| 222.40 MINR | +84.41% | |
| 120.60 MINR | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
R J Biotech Stock analysis
Frequently Asked Questions about R J Biotech stock
Current Assets of R J Biotech is 2.90 M INR in 2022.
Current Assets of R J Biotech changed from 36.31 M INR to 2.90 M INR, representing a -92.01% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Assets R J Biotech since 2006 – with annual values, charts, and detailed analysis.
Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.
Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's R J Biotech historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — R J Biotech
All Key Metrics — R J Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth